<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03734432</url>
  </required_header>
  <id_info>
    <org_study_id>IGAR-TO-007</org_study_id>
    <nct_id>NCT03734432</nct_id>
  </id_info>
  <brief_title>IGAR-Breast TeleOp Trial</brief_title>
  <acronym>IGAR-Breast-TO</acronym>
  <official_title>IGAR-Breast Teleoperative Clinical Investigation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to answer the question: can the IGAR-Breast safely and effectively
      perform teleoperative breast biopsies? This is a prospective, pilot trial. 5-10 participants
      will be selected by the radiologist and the success of biopsy analyzed. In addition the
      number of adverse events, device events and procedural deviations will be assessed to
      determine safety and efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective clinical trial, patients who present to the breast cancer clinic at one
      of the primary sites with suspected breast cancer requiring MRI-guided biopsy for diagnosis
      or staging will be screened consecutively. Patients who meet the inclusion criteria will be
      approached for consent to participate in the study. Upon consent, each participant will
      undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while
      the radiologist operates the system from a remote site. All consenting participants will be
      followed up for the assessment of the secondary outcome measure.

      A total of 5-10 participants will be consented for the pilot investigation.

      Each individual subject's participation is estimated to last approximately one week post
      procedure, with the trial itself expected to be completed within one year of its start date.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ability for IGAR-Breast to perform breast biopsies teleoperatively</measure>
    <time_frame>at time of sampling and pathological evaluation</time_frame>
    <description>analyzing the frequency of successful biopsy, in which the samples collected are of diagnostic quality as determined by radiologist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number and frequency of adverse events, device events and procedural deviations in addition to a comparison to results from previous trials for efficacy</measure>
    <time_frame>During procedure</time_frame>
    <description>The number of times the local radiologist is required to participate will also be observed from a safety perspective</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IGAR-Breast TeleOp</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IGAR-Breast TeleOp</intervention_name>
    <description>Upon consent, each participant will undergo a teleoperative breast biopsy at their local site using the IGAR-Breast system, while the radiologist operates the system from a remote site.</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects aged ≥ 18 years who require MRI-guided breast biopsy for diagnosis
             and/or staging Subjects are able to tolerate procedures for the MRI

        Exclusion Criteria:

          -  Subjects who refuse or are unable to give free and informed consent Subjects requiring
             more than one breast biopsy Subjects with breast implants or other foreign bodies
             Subjects for whom investigator determines IGAR-Breast enabled MRI-guided breast biopsy
             is not possible (size of subject, location of lesion, size of breast, etc.) Subjects
             who are pregnant or who plan to become pregnant during the course of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female subjects aged ≥ 18 years who require MRI-guided breast biopsy for diagnosis and/or staging Subjects are able to tolerate procedures for the MRI</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehran Anvari</last_name>
    <role>Principal Investigator</role>
    <affiliation>Csii/St Joseph's Healthcare Hamilton</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Barlow</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>33739</phone_ext>
    <email>kbarlow@stjoes.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Josephs Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Mehran Anvari</last_name>
      <phone>9055221155</phone>
      <phone_ext>35058</phone_ext>
      <email>anvari@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Karen Barlow</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>33739</phone_ext>
      <email>kbarlow@stjoes.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mehran Anvari</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colm Boylan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Belinda Curpen</last_name>
      <email>Belinda.Curpen@sunnybrook.ca</email>
    </contact>
    <contact_backup>
      <last_name>Carrie Betel</last_name>
      <email>carrie.betel@sunnybrook.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Belinda Curpen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carrie Betel</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Calvin Law</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imagix - Radiologie Saint-Laurent</name>
      <address>
        <city>Saint-Laurent</city>
        <state>Quebec</state>
        <zip>H4R 0B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Nathalie Duchesne</last_name>
      <email>nathalie.duchesne@me.com</email>
    </contact>
    <investigator>
      <last_name>Nathalie Duchesne</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>November 6, 2018</last_update_submitted>
  <last_update_submitted_qc>November 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diagnostic, Imaging, MRI</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

